UHS · NYQ · Healthcare
Universal Health Services, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 283.40
Market price
USD 176.69
Implied upside
+60.4%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 18.9bn | USD 20.6bn | USD 22.5bn | USD 24.5bn | USD 26.7bn | +9.0% |
| EBIT | USD 1.8bn | USD 2.0bn | USD 2.1bn | USD 2.3bn | USD 2.5bn | +9.0% |
| NOPAT | USD 1.4bn | USD 1.5bn | USD 1.7bn | USD 1.8bn | USD 2.0bn | +9.0% |
| Add depreciation & amortisation | USD 737.3m | USD 803.9m | USD 876.4m | USD 955.5m | USD 1.0bn | +9.0% |
| Less capital expenditure | USD -1.1bn | USD -1.2bn | USD -1.3bn | USD -1.4bn | USD -1.5bn | +9.0% |
| Less increase in working capital | USD 30.3m | USD 33.0m | USD 36.0m | USD 39.3m | USD 42.8m | -9.0% |
| Free cashflow to firm | USD 1.1bn | USD 1.2bn | USD 1.3bn | USD 1.4bn | USD 1.6bn | +9.0% |
| Discount factor | 0.9601 | 0.8851 | 0.8159 | 0.7522 | 0.6934 | - |
| Present value | USD 1.1bn | USD 1.1bn | USD 1.1bn | USD 1.1bn | USD 1.1bn | +0.5% |
| Present Value Of The Forecast | USD 5.4bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.041 | Reported 1.061, pulled toward 1.0 (Blume) |
| Cost of equity | 10.72% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 10.4bn | 66.8% of capital |
| Total debt | USD 5.2bn | 33.2% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.48% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
77% of EV
- Forecast FCFF, final year
- USD 1.6bn
- Capex at depreciation, working capital in reinvestment
- USD 2.0bn
- Less reinvestment at g/ROIC (24.6% of NOPAT)
- USD -492.5m
- Capitalised
- USD 1.5bn
- ROIC (reported)
- 10.1%
- Terminal value, undiscounted
- USD 25.8bn
- Terminal value, discounted
- USD 17.9bn
- Enterprise value
- USD 23.3bn
- Less net debt
- USD 5.0bn
- Equity value
- USD 18.3bn
Exit at 5.9x EBITDA
73% of EV
- Terminal value, undiscounted
- USD 21.1bn
- Terminal value, discounted
- USD 14.6bn
- Enterprise value
- USD 20.0bn
- Less net debt
- USD 5.0bn
- Equity value
- USD 15.0bn
Spread between methods: 20%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.48% | 415.86 | 437.21 | 463.65 | 497.35 | 541.99 |
| 7.48% | 331.89 | 342.68 | 355.40 | 370.73 | 389.63 |
| 8.48% | 272.08 | 277.39 | 283.40 | 290.32 | 298.41 |
| 9.48% | 227.34 | 229.61 | 232.05 | 234.71 | 237.65 |
| 10.48% | 193.68 | 194.63 | 195.57 | 196.52 | 197.46 |
Outlined: this model. Green text: above today's price of 176.69. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 9.0% | 1.0% | -8.0pp |
| EBIT margin | 9.5% | 6.8% | -2.6pp |
| Discount rate | 8.5% | 11.2% | +2.7pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.